Skip to main content

Box 3 Societal issues

From: Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public

• Costs should not play a role in the selection of a diagnostic method for CAA
• Society should primarily invest in the provision of good care for people with dementia, not in research into medication
• When an instrument will be available to measure CAA in healthy people, then the results should be shared with family, colleagues, insurance and employers
• It is a good idea to have a CAA-screening program for healthy people, for this will foster research into the natural development of the disease or into medication that serves the health of future patients
• Empty card